Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5012018> ?p ?o }
Showing triples 1 to 45 of
45
with 100 triples per page.
- Q5012018 subject Q7336348.
- Q5012018 subject Q8501361.
- Q5012018 subject Q8522216.
- Q5012018 abstract "CJC-1295, also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies. It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regards to half-life.CJC-1295 markedly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans. With a single injection, in human subjects, CJC-1295 increases plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 1.5- to 3-fold for 9 to 11 days. The drug has an estimated half-life of about 6 to 8 days in humans. With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days.CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormone-releasing hormone 1-29 and stimulate insulin-like growth factor 1 secretion. It increases the half-life of acting agents by bioconjugation.CJC-1295 was under investigation for the treatment of lipodystrophy and growth hormone deficiency and reached phase II clinical trials but was discontinued upon the death of one of the trial subjects. The attending physician of the trial believed that the most likely explanation for the incident was that the patient had asymptomatic coronary artery disease with plaque rupture and occlusion, and that the occurrence was unrelated to treatment with CJC-1295. In any case, research was terminated nonetheless as a precaution. CJC-1295 has found black market use for bodybuilding purposes, with this, in some countries such as the Netherlands, being an illicit use.".
- Q5012018 atcPrefix "None".
- Q5012018 casNumber "863288-34-0".
- Q5012018 pubchem "56841945".
- Q5012018 wikiPageExternalLink 800018006.
- Q5012018 wikiPageWikiLink Q124100.
- Q5012018 wikiPageWikiLink Q14863714.
- Q5012018 wikiPageWikiLink Q1538213.
- Q5012018 wikiPageWikiLink Q174211.
- Q5012018 wikiPageWikiLink Q190199.
- Q5012018 wikiPageWikiLink Q2035485.
- Q5012018 wikiPageWikiLink Q20707766.
- Q5012018 wikiPageWikiLink Q30612.
- Q5012018 wikiPageWikiLink Q323936.
- Q5012018 wikiPageWikiLink Q369262.
- Q5012018 wikiPageWikiLink Q409489.
- Q5012018 wikiPageWikiLink Q4551312.
- Q5012018 wikiPageWikiLink Q47270.
- Q5012018 wikiPageWikiLink Q485014.
- Q5012018 wikiPageWikiLink Q4914729.
- Q5012018 wikiPageWikiLink Q50851.
- Q5012018 wikiPageWikiLink Q5161136.
- Q5012018 wikiPageWikiLink Q55.
- Q5012018 wikiPageWikiLink Q6889403.
- Q5012018 wikiPageWikiLink Q7180990.
- Q5012018 wikiPageWikiLink Q7336348.
- Q5012018 wikiPageWikiLink Q7455005.
- Q5012018 wikiPageWikiLink Q7705415.
- Q5012018 wikiPageWikiLink Q79749.
- Q5012018 wikiPageWikiLink Q844935.
- Q5012018 wikiPageWikiLink Q8501361.
- Q5012018 wikiPageWikiLink Q8522216.
- Q5012018 atcPrefix "None".
- Q5012018 casNumber "863288".
- Q5012018 pubchem "56841945".
- Q5012018 type ChemicalSubstance.
- Q5012018 type Drug.
- Q5012018 type ChemicalObject.
- Q5012018 type Thing.
- Q5012018 type Q8386.
- Q5012018 comment "CJC-1295, also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies.".
- Q5012018 label "CJC-1295".